These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 23582471)

  • 1. Microtools for single-cell analysis in biopharmaceutical development and manufacturing.
    Love KR; Bagh S; Choi J; Love JC
    Trends Biotechnol; 2013 May; 31(5):280-6. PubMed ID: 23582471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins.
    van Beers MM; Bardor M
    Biotechnol J; 2012 Dec; 7(12):1473-84. PubMed ID: 23027660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biopharmaceuticals in China.
    Hu X; Ma Q; Zhang S
    Biotechnol J; 2006 Nov; 1(11):1215-24. PubMed ID: 17089435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Market access for biopharmaceuticals: new challenges.
    Simon F
    Health Aff (Millwood); 2006; 25(5):1363-70. PubMed ID: 16966734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new large-scale manufacturing platform for complex biopharmaceuticals.
    Vogel JH; Nguyen H; Giovannini R; Ignowski J; Garger S; Salgotra A; Tom J
    Biotechnol Bioeng; 2012 Dec; 109(12):3049-58. PubMed ID: 22688835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The therapeutic antibodies market to 2008.
    Pavlou AK; Belsey MJ
    Eur J Pharm Biopharm; 2005 Apr; 59(3):389-96. PubMed ID: 15760719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hybrid modeling for quality by design and PAT-benefits and challenges of applications in biopharmaceutical industry.
    von Stosch M; Davy S; Francois K; Galvanauskas V; Hamelink JM; Luebbert A; Mayer M; Oliveira R; O'Kennedy R; Rice P; Glassey J
    Biotechnol J; 2014 Jun; 9(6):719-26. PubMed ID: 24806479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formulation and manufacturability of biologics.
    Shire SJ
    Curr Opin Biotechnol; 2009 Dec; 20(6):708-14. PubMed ID: 19880308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multivariate PAT solutions for biopharmaceutical cultivation: current progress and limitations.
    Mercier SM; Diepenbroek B; Wijffels RH; Streefland M
    Trends Biotechnol; 2014 Jun; 32(6):329-36. PubMed ID: 24732022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flexibility--the guiding principle for antibody manufacturing.
    Carson KL
    Nat Biotechnol; 2005 Sep; 23(9):1054-8. PubMed ID: 16151390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conference scene: recent advancements in microscale bioprocess development.
    Guy H
    Immunotherapy; 2012 Feb; 4(2):145-7. PubMed ID: 22339457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A special report on India's biotech scenario: advancement in biopharmaceutical and health care sectors.
    Chakraborty C; Agoramoorthy G
    Biotechnol Adv; 2010; 28(1):1-6. PubMed ID: 19931371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Large scale demonstration of a process analytical technology application in bioprocessing: use of on-line high performance liquid chromatography for making real time pooling decisions for process chromatography.
    Rathore AS; Parr L; Dermawan S; Lawson K; Lu Y
    Biotechnol Prog; 2010; 26(2):448-57. PubMed ID: 19927320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medium term planning of biopharmaceutical manufacture using mathematical programming.
    Lakhdar K; Zhou Y; Savery J; Titchener-Hooker NJ; Papageorgiou LG
    Biotechnol Prog; 2005; 21(5):1478-89. PubMed ID: 16209554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early implementation of QbD in biopharmaceutical development: a practical example.
    Zurdo J; Arnell A; Obrezanova O; Smith N; Gómez de la Cuesta R; Gallagher TR; Michael R; Stallwood Y; Ekblad C; Abrahmsén L; Höidén-Guthenberg I
    Biomed Res Int; 2015; 2015():605427. PubMed ID: 26075248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mammalian cell protein expression for biopharmaceutical production.
    Zhu J
    Biotechnol Adv; 2012; 30(5):1158-70. PubMed ID: 21968146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational engineering of Escherichia coli strains for plasmid biopharmaceutical manufacturing.
    Gonçalves GA; Bower DM; Prazeres DM; Monteiro GA; Prather KL
    Biotechnol J; 2012 Feb; 7(2):251-61. PubMed ID: 21913330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A decision-support model for evaluating changes in biopharmaceutical manufacturing processes.
    Chhatre S; Francis R; O'Donovan K; Titchener-Hooker NJ; Newcombe AR; Keshavarz-Moore E
    Bioprocess Biosyst Eng; 2007 Jan; 30(1):1-11. PubMed ID: 17093973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Building biomanufacturing capacity--the chapter and verse.
    Kamarck ME
    Nat Biotechnol; 2006 May; 24(5):503-5. PubMed ID: 16680126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.